Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
暂无分享，去创建一个
M. Kudo | A. Zhu | R. Finn | T. Yau | B. Daniele | C. Verslype | V. Zagonel | A. Cheng | J. Knox | S. Chan | A. Vogel | S. Cattan | A. Siegel | G. Verset | D. Sarker | L. Fartoux | S. Ogasawara | J. Edeline | D. H. Palmer | A. Wang | E. Gurary | Anran Wang